Oxford Nanopore Technologies and A.D.A.M. Innovations have announced a collaboration to develop and deploy advanced genomic medicine applications in Japan. The agreement aims to introduce nanopore sequencing into clinical workflows to support faster and more precise genomic testing.
Collaboration focuses on clinical genomics in Japan
The initial phase of the collaboration is intended to establish Oxford Nanopore’s real-time sequencing technology across A.D.A.M. Innovations’ genetic testing portfolio. The companies said the goal is to support genomic testing across multiple disease areas using Japan-specific validation standards.
Nanopore sequencing can analyse DNA fragments of any length and capture more complete genomic information than some existing sequencing approaches. As a result, the partners said the collaboration is intended to improve testing accuracy and broaden clinical applications.
Agreement signed in Tokyo
A memorandum of understanding was signed at the British Embassy in Tokyo during an event supported by the UK ambassador to Japan. The announcement highlights a broader effort to expand scientific and industrial collaboration between the UK and Japan.
The companies said the partnership aligns with the 2024 UK–Japan Health Memorandum of Cooperation, which supports bilateral work in genomics and healthcare innovation.
Partnership supports precision medicine strategy
A.D.A.M. Innovations, also known in Japan as Genesis Healthcare Co., is one of the country’s established genetic testing companies. Under the collaboration, the company is expected to evaluate how nanopore sequencing can be incorporated into clinical pathways across a range of conditions and diseases.
Oxford Nanopore said the initiative is designed to support scalable sequencing and more information-rich genomic analysis, with the longer-term aim of expanding precision medicine in Japan.
Broader life sciences cooperation between the UK and Japan
The collaboration also reflects wider UK government support for bilateral life sciences partnerships. In addition, the companies said the project could contribute to translational research and the development of new clinical workflows in genomic medicine.
Further information is available on the Oxford Nanopore Technologies website. Related coverage can be found in the Biotechnology section.
